Get started
Sonnet BioTherapeutics Holdings, Inc.SS

Sonnet BioTherapeutics Holdings, Inc.

1.11USDR
−0.09−7.50%
As of today at 18:35 GMT
USD
No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

SONN chart


Full chart

SONN upcoming earnings


Next report date
≈
August 18
Report period
Q3 2025
EPS estimate
−0.49 USD
Revenue estimate
0.00 USD

Key stats


Market capitalization
‪3.51 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−12.83 USD
Net income (FY)
‪−7.44 M‬ USD
Revenue (FY)
‪18.63 K‬ USD
Shares float
‪3.13 M‬
Beta (1Y)
0.25

Employees


Employees (FY)
13
Change (1Y)
+1 +8.33%
Revenue / Employee (1Y)
‪1.43 K‬ USD
Net income / Employee (1Y)
‪−572.09 K‬ USD

About Sonnet BioTherapeutics Holdings, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Raghu Rao
Website
sonnetbio.com
Headquarters
Princeton
Founded
2011
FIGI
BBG000BVZ4N6
Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline focuses on cytokines, a class of cell signaling peptides that, among other important functions, serve as potent immunomodulatory agents. The company was founded by Pankaj Mohan and John K. Cini in 2011 and is headquartered in Princeton, NJ.

Financials


Performance
‪−318.0%‬
‪−313.5%‬
‪−309.0%‬
‪−304.5%‬
‪−300.0%‬
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪‪−3.60 M‬‬
‪‪−2.40 M‬‬
‪‪−1.20 M‬‬
‪0.00‬
‪‪1.20 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−4.40 M‬‬
‪‪−3.30 M‬‬
‪‪−2.20 M‬‬
‪‪−1.10 M‬‬
‪0.00‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−3.60 M‬‬
‪‪−2.70 M‬‬
‪‪−1.80 M‬‬
‪‪−900.00 K‬‬
‪0.00‬
Debt level and coverage
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪‪−5.00 M‬‬
‪‪−2.50 M‬‬
‪0.00‬
‪‪2.50 M‬‬
‪‪5.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Earnings
Next:Aug 18, 2025
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
‪−6.40‬
‪−4.80‬
‪−3.20‬
‪−1.60‬
‪0.00‬
Actual
Estimate

SONN news



No news here

Looks like there's nothing to report right now

Reload

Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of SONN is 1.11 USD — it has decreased by −7.50% in the past 24 hours. Watch Sonnet BioTherapeutics Holdings, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Sonnet BioTherapeutics Holdings, Inc. stocks are traded under the ticker SONN.
SONN stock has fallen by −6.98% compared to the previous week, the month change is a −3.51% fall, over the last year Sonnet BioTherapeutics Holdings, Inc. has showed a −92.02% decrease.
We've gathered analysts' opinions on Sonnet BioTherapeutics Holdings, Inc. future price: according to them, SONN price has a max estimate of 20.00 USD and a min estimate of 20.00 USD. Watch SONN chart and read a more detailed Sonnet BioTherapeutics Holdings, Inc. stock forecast: see what analysts think of Sonnet BioTherapeutics Holdings, Inc. and suggest that you do with its stocks.
SONN reached its all-time high on Jul 27, 2005 with the price of 9,609,600.00 USD, and its all-time low was 1.10 USD and was reached on Apr 7, 2025. View more price dynamics on SONN chart.
See other stocks reaching their highest and lowest prices.
SONN stock is 15.74% volatile and has beta coefficient of 0.25. Track Sonnet BioTherapeutics Holdings, Inc. stock price on the chart and check out the list of the most volatile stocks — is Sonnet BioTherapeutics Holdings, Inc. there?
Yes, you can track Sonnet BioTherapeutics Holdings, Inc. financials in yearly and quarterly reports right on TradingView.
Sonnet BioTherapeutics Holdings, Inc. is going to release the next earnings report on Aug 18, 2025. Keep track of upcoming events with our Earnings Calendar.
SONN net income for the last quarter is ‪−3.49 M‬ USD, while the quarter before that showed ‪−3.16 M‬ USD of net income which accounts for −10.45% change. Track more Sonnet BioTherapeutics Holdings, Inc. financial stats to get the full picture.
No, SONN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 22, 2025, the company has 13 employees. See our rating of the largest employees — is Sonnet BioTherapeutics Holdings, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Sonnet BioTherapeutics Holdings, Inc. EBITDA is ‪−13.68 M‬ USD, and current EBITDA margin is ‪−63.11 K‬%. See more stats in Sonnet BioTherapeutics Holdings, Inc. financial statements.
Like other stocks, SONN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Sonnet BioTherapeutics Holdings, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Sonnet BioTherapeutics Holdings, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Sonnet BioTherapeutics Holdings, Inc. stock shows the sell signal. See more of Sonnet BioTherapeutics Holdings, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.